Skip to main content

Table 5 Echocardiographic results of mice after inhibition of HDAC3 and miR-18a and overexpression of ADRB3

From: The crosstalk of HDAC3, microRNA-18a and ADRB3 in the progression of heart failure

Group\parameter LVPWD (mm) IVSD (mm) LVEDD (mm) LVESD (mm) LVEF (%) LVFS (%)
HF + sh-NC 1.31 ± 0.16 0.81 ± 0.09 4.42 ± 0.54 3.91 ± 0.45 15.47 ± 1.78 11.31 ± 1.33
HF + sh-HDAC3 1.88 ± 0.19 * 0.54 ± 0.07 * 3.79 ± 0.41 * 2.57 ± 0.23 * 31.97 ± 4.49 * 32.13 ± 1.84 *
HF + sh-HDAC3 + NC-antagomir 1.96 ± 0.22 0.63 ± 0.07 4.01 ± 0.32 2.74 ± 0.20 31.44 ± 3.83 30.68 ± 2.68
HF + sh-HDAC3 + miR-18a-antagomir 1.63 ± 0.14 # 0.96 ± 0.11 # 4.88 ± 0.43 # 3.68 ± 0.34 # 24.68 ± 2.43 # 24.39 ± 2.17 #
HF + sh-HDAC3 + oe-NC 1.82 ± 0.21 0.61 ± 0.07 3.87 ± 0.32 2.60 ± 0.21 32.80 ± 3.42 29.97 ± 2.19
HF + sh-HDAC3 + oe-ADRB3 1.56 ± 0.17 & 0.92 ± 0.09 & 4.53 ± 0.43 & 3.90 ± 0.34 & 13.96 ± 1.26 & 14.57 ± 1.14 &
  1. * p < 0.05 vs. HF mice treated with sh-NC. # p < 0.05 vs. HF mice treated with sh-HDAC3 + NC-antagomir. & p < 0.05 vs. HF mice treated with sh-HDAC3 + oe-NC. One-way ANOVA was utilized for comparisons among multiple groups, and Tukey’s post-hoc test was employed for intra-group pairwise comparison